Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children
NCT ID: NCT01091818
Last Updated: 2011-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
40 participants
INTERVENTIONAL
2010-03-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators' primary hypothesis is that time from end of medication to extubation will be shorter with dexmedetomidine sedation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation
NCT01519167
Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation
NCT00878345
Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion
NCT02134327
Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)
NCT00481312
A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children
NCT02459509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
midazolam
Midazolam
Midazolam is given as major sedative drug
dexmedetomidin
dexmedetomidine
Dexemedethomidine is given as major sedative drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexmedetomidine
Dexemedethomidine is given as major sedative drug
Midazolam
Midazolam is given as major sedative drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age between 2 and 18 years
* anticipated need of respirator treatment for more than 24 hrs
* included in study within 48 hrs of admission to intensive care unit (ICU)
Exclusion Criteria
* severe intracranial or spinal trauma with circulatory instability
* sever bradycardia or atrioventricular (A-V) block
* liver failure
* less than 50% chance of anticipated survival
* known allergy to study drugs
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ullevaal University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Oslo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept of Anesthesiology, Oslo University Hospital, Ullevaal
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
dexmedetmidazchildintsed
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.